Insider Buying: Harvard Bioscience, Inc. (NASDAQ:HBIO) CEO Purchases 20,000 Shares of Stock

Harvard Bioscience, Inc. (NASDAQ:HBIOGet Free Report) CEO James W. Green bought 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 6th. The stock was acquired at an average price of $3.07 per share, for a total transaction of $61,400.00. Following the transaction, the chief executive officer now owns 3,101,091 shares in the company, valued at $9,520,349.37. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Harvard Bioscience Price Performance

Shares of Harvard Bioscience stock opened at $2.94 on Friday. The firm has a market cap of $127.68 million, a PE ratio of -14.70 and a beta of 1.25. Harvard Bioscience, Inc. has a 12-month low of $2.92 and a 12-month high of $6.20. The company has a quick ratio of 0.94, a current ratio of 1.88 and a debt-to-equity ratio of 0.46. The company’s fifty day simple moving average is $3.68 and its two-hundred day simple moving average is $4.29.

Harvard Bioscience (NASDAQ:HBIOGet Free Report) last announced its quarterly earnings results on Thursday, March 7th. The medical instruments supplier reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The firm had revenue of $28.15 million during the quarter, compared to the consensus estimate of $27.80 million. Harvard Bioscience had a positive return on equity of 0.26% and a negative net margin of 8.18%. As a group, equities analysts expect that Harvard Bioscience, Inc. will post 0.11 EPS for the current year.

Analyst Ratings Changes

Separately, StockNews.com cut shares of Harvard Bioscience from a “buy” rating to a “hold” rating in a research report on Thursday, May 9th.

View Our Latest Analysis on Harvard Bioscience

Institutional Investors Weigh In On Harvard Bioscience

Large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp raised its holdings in Harvard Bioscience by 1.2% in the third quarter. Bank of New York Mellon Corp now owns 227,002 shares of the medical instruments supplier’s stock worth $976,000 after buying an additional 2,758 shares during the last quarter. WINTON GROUP Ltd raised its holdings in Harvard Bioscience by 140.8% in the third quarter. WINTON GROUP Ltd now owns 87,765 shares of the medical instruments supplier’s stock worth $377,000 after buying an additional 51,316 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Harvard Bioscience by 64.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 161,819 shares of the medical instruments supplier’s stock worth $696,000 after buying an additional 63,174 shares during the last quarter. B. Riley Asset Management LLC raised its holdings in Harvard Bioscience by 6.5% in the third quarter. B. Riley Asset Management LLC now owns 3,262,995 shares of the medical instruments supplier’s stock worth $14,031,000 after buying an additional 200,032 shares during the last quarter. Finally, New York State Common Retirement Fund raised its holdings in Harvard Bioscience by 3.2% in the fourth quarter. New York State Common Retirement Fund now owns 142,460 shares of the medical instruments supplier’s stock worth $762,000 after buying an additional 4,463 shares during the last quarter. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

(Get Free Report)

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.

Featured Articles

Receive News & Ratings for Harvard Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harvard Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.